Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report released on Tuesday.
Several other equities research analysts have also commented on RYTM. Bank of America assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They set a “buy” rating and a $30.00 target price on the stock. Cowen restated a “buy” rating and set a $40.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Needham & Company LLC restated a “buy” rating and set a $32.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Finally, Morgan Stanley assumed coverage on shares of Rhythm Pharmaceuticals in a research report on Monday, October 30th. They issued an “equal weight” rating and a $23.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $31.25.
Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) opened at $29.04 on Tuesday. Rhythm Pharmaceuticals has a 1 year low of $21.38 and a 1 year high of $33.81.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.